A Phase 1b Pharmacodynamic Study of Durvalumab (MEDI4736) in Patients With HER-2 Positive Metastatic Breast Cancer (MBC) Receiving Trastuzumab
The purpose of this study is to find the highest dose of durvalumab that can be tolerated
without causing very severe side effects when receiving standard treatment and to see what
effects the study drug has on this type of cancer.
The researchers doing this study are also interested in looking for markers that will help
predict which patients are most likely to be helped by durvalumab when receiving standard
treatment and what effects durvalumab has on this type of cancer.
View this trial on ClinicalTrials.gov
Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.
These resources are provided in partnership with the
Canadian Cancer Society